David A. Siegel Corvus Pharmaceuticals, Inc. Transaction History
Two Sigma Advisers, LP
- $43.8 Billion
- Q2 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Corvus Pharmaceuticals, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 113,400 shares of CRVS stock, worth $1.07 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
113,400
Previous 185,100
38.74%
Holding current value
$1.07 Million
Previous $329,000
37.39%
% of portfolio
0.0%
Previous 0.0%
Shares
18 transactions
Others Institutions Holding CRVS
# of Institutions
55Shares Held
27.9MCall Options Held
22.9KPut Options Held
29.8K-
Orbimed Advisors LLC San Diego, CA6.94MShares$65.3 Million0.3% of portfolio
-
Samlyn Capital, LLC New York, NY6.12MShares$57.6 Million0.2% of portfolio
-
Steven Cohen Point72 Asset Management, L.P. | Stamford, Ct5.96MShares$56.1 Million0.03% of portfolio
-
Adams Street Partners LLC Chicago, IL3.28MShares$30.8 Million2.69% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.65MShares$15.5 Million0.0% of portfolio
About Corvus Pharmaceuticals, Inc.
- Ticker CRVS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,553,500
- Market Cap $438M
- Description
- Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The compan...